Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

Phase 3

Terminated

Conditions: Hepatitis C, Chronic

Interventions: Drug: Previous treatment in DEB025 study

First Posted Date: 2015-06-08

Last Posted Date: 2018-01-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT02465203

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Ceritinib Rare Indications Study in ALK+ Tumors

Phase 2

Terminated

Conditions: Tumors With Aberrations in ALK
Anaplastic Large Cell Lymphoma
Inflammatory Myofibroblastic Tumor
Glioblastoma

Interventions: Drug: Ceritinib (LDK378)

First Posted Date: 2015-06-08

Last Posted Date: 2019-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 22

Registration Number: NCT02465528

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: LAG525
Drug: PDR001

First Posted Date: 2015-06-02

Last Posted Date: 2022-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 490

Registration Number: NCT02460224

Locations: 🇺🇸
Duke Clinical Research Institute SC, Durham, North Carolina, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center SC, New York, New York, United States

and more 4 locations

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

Phase 1

Terminated

Conditions: Metastatic and Advanced Solid Tumors

Interventions: Drug: PDR001
Drug: NIZ985

First Posted Date: 2015-05-22

Last Posted Date: 2023-03-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 83

Registration Number: NCT02452268

Locations: 🇺🇸
Washington University School of Medicine SC, Saint Louis, Missouri, United States
🇺🇸
National Cancer Institute National Cancer Institute, Bethesda, Maryland, United States
🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 4 locations

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: LDK378

First Posted Date: 2015-05-21

Last Posted Date: 2021-03-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT02450903

Locations: 🇯🇵
Novartis Investigative Site, Koto ku, Tokyo, Japan

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease, COPD

Interventions: Drug: QBW251
Drug: Placebo

First Posted Date: 2015-05-20

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 92

Registration Number: NCT02449018

Locations: 🇵🇱
Novartis Investigative Site, Sobotka, Poland

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Phase 2

Completed

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)

Interventions: Biological: Tisagenlecleucel
Drug: Lymphodepleting chemotherapy

First Posted Date: 2015-05-15

Last Posted Date: 2024-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 115

Registration Number: NCT02445248

Locations: 🇺🇸
University of Chicago Medical Center Hematology and Oncology SC - CTL019B2207J, Chicago, Illinois, United States
🇺🇸
University of Kansas Cancer Center SC - CTL019C2201, Westwood, Kansas, United States
🇺🇸
MD Anderson Cancer Center SC, Houston, Texas, United States

and more 10 locations

CAR-T Long Term Follow Up (LTFU) Study

Phase 3

Recruiting

Conditions: Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

Interventions: Genetic: Previously treated CAR-T patients

First Posted Date: 2015-05-15

Last Posted Date: 2025-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1400

Registration Number: NCT02445222

Locations: 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 27 locations

Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease, COPD

Interventions: Drug: QVA149
Drug: Placebo

First Posted Date: 2015-05-13

Last Posted Date: 2019-01-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT02442206

Locations: 🇩🇪
Novartis Investigative Site, Hannover, Germany

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Alpelisib
Drug: Placebo

First Posted Date: 2015-05-07

Last Posted Date: 2025-02-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 572

Registration Number: NCT02437318

Locations: 🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States

and more 32 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy